Helen I. Torley received $12.7M in total compensation as President andChief Executive Officer of HALOZYME THERAPEUTICS, INC. in FY2024. The largest component was $8.8M in stock awards. That’s up 8% from FY2023. Source: SEC DEF 14A.
Executive Compensation Summary for HALOZYME THERAPEUTICS, INC.
Helen I. Torley Salary and Compensation - HALOZYME THERAPEUTICS, INC. CEO Pay 2024
In fiscal year 2024, Helen I. Torley, President andChief Executive Officer of HALOZYME THERAPEUTICS, INC. (HALO), received total compensation of $12.7 million.
Helen I. Torley's compensation breakdown includes: base salary of $960K, stock awards valued at $8.8 million, option awards of $1.6 million, non-equity incentive compensation of $1.4 million, and other compensation of $18K.
Compared to fiscal year 2023, Helen I. Torley's total compensation increased 8% from $11.8 million to $12.7 million.
HALOZYME THERAPEUTICS, INC. (HALO) Executive Pay 2024
HALOZYME THERAPEUTICS, INC.'s top 4 named executive officers received combined total compensation of $25.4 million in fiscal year 2024.
The named executive officers disclosed in HALOZYME THERAPEUTICS, INC.'s 2024 proxy statement are:Helen I. Torley (President andChief Executive Officer) with total compensation of $12.7 million, Mark Snyder (Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary) with total compensation of $5.4 million, Nicole LaBrosse (Senior Vice President,Chief Financial Officer) with total compensation of $4.2 million, and Michael J. LaBarre (Senior Vice President, Chief Technical Officer) with total compensation of $3.0 million.